Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia

H. Gao, B. N. Lee, M. Talpaz, N. J. Donato, J. E. Cortes, H. M. Kantarjian, J. M. Reuben

Research output: Contribution to journalArticle

Abstract

Although imatinib mesylate (IM) is highly effective at inducing complete cytogenetic remission in patients with chronic myelogenous leukemia (CML), it is known to suppress T-cell proliferation in vitro. As cytokines are required for T-cell proliferation, we investigated the effects of IM on cytokine synthesis by T cells of CML patients by assessing cytokine synthesis by activated CD4+ and CD8+ T cells in vitro. The activation of T cells in the whole blood of IM-treated patients (CML-IM) with Staphylococcus enterotoxin B resulted in significantly lower percentages of CD4+ T cells that synthesized interleukin 2 (P = 0.017), interferon-gamma (P = 0.010), and tumor necrosis factor-alpha (P = 0.009) than did the activated T cells of control subjects. The addition of exogenous IM to the cultures of peripheral blood mononuclear cells of CML-IM patients reduced Th1 cytokine synthesis by the CD4+ T cells. Furthermore, IM therapy at clinical doses suppressed the tyrosine phosphorylation of ZAP70. These findings suggest that inhibition of ZAP70 signaling pathway and suppression of Th1 cytokine synthesis by CD4+ T cells required the presence of IM at the time of T-cell activation through the T-cell receptor.

Original languageEnglish (US)
Pages (from-to)1905-1911
Number of pages7
JournalLeukemia
Volume19
Issue number11
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytokines
T-Lymphocytes
Cell Proliferation
Imatinib Mesylate
T-Cell Antigen Receptor
Cytogenetics
Interferon-gamma
Interleukin-2
Tyrosine
Blood Cells
Tumor Necrosis Factor-alpha
Phosphorylation

Keywords

  • Chronic myelogenous leukemia
  • Cytokines
  • Imatinib mesylate
  • T cells

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. / Gao, H.; Lee, B. N.; Talpaz, M.; Donato, N. J.; Cortes, J. E.; Kantarjian, H. M.; Reuben, J. M.

In: Leukemia, Vol. 19, No. 11, 11.2005, p. 1905-1911.

Research output: Contribution to journalArticle

Gao, H. ; Lee, B. N. ; Talpaz, M. ; Donato, N. J. ; Cortes, J. E. ; Kantarjian, H. M. ; Reuben, J. M. / Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. In: Leukemia. 2005 ; Vol. 19, No. 11. pp. 1905-1911.
@article{eee6260799624736be66b274abbe1b7e,
title = "Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia",
abstract = "Although imatinib mesylate (IM) is highly effective at inducing complete cytogenetic remission in patients with chronic myelogenous leukemia (CML), it is known to suppress T-cell proliferation in vitro. As cytokines are required for T-cell proliferation, we investigated the effects of IM on cytokine synthesis by T cells of CML patients by assessing cytokine synthesis by activated CD4+ and CD8+ T cells in vitro. The activation of T cells in the whole blood of IM-treated patients (CML-IM) with Staphylococcus enterotoxin B resulted in significantly lower percentages of CD4+ T cells that synthesized interleukin 2 (P = 0.017), interferon-gamma (P = 0.010), and tumor necrosis factor-alpha (P = 0.009) than did the activated T cells of control subjects. The addition of exogenous IM to the cultures of peripheral blood mononuclear cells of CML-IM patients reduced Th1 cytokine synthesis by the CD4+ T cells. Furthermore, IM therapy at clinical doses suppressed the tyrosine phosphorylation of ZAP70. These findings suggest that inhibition of ZAP70 signaling pathway and suppression of Th1 cytokine synthesis by CD4+ T cells required the presence of IM at the time of T-cell activation through the T-cell receptor.",
keywords = "Chronic myelogenous leukemia, Cytokines, Imatinib mesylate, T cells",
author = "H. Gao and Lee, {B. N.} and M. Talpaz and Donato, {N. J.} and Cortes, {J. E.} and Kantarjian, {H. M.} and Reuben, {J. M.}",
year = "2005",
month = "11",
doi = "10.1038/sj.leu.2403933",
language = "English (US)",
volume = "19",
pages = "1905--1911",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia

AU - Gao, H.

AU - Lee, B. N.

AU - Talpaz, M.

AU - Donato, N. J.

AU - Cortes, J. E.

AU - Kantarjian, H. M.

AU - Reuben, J. M.

PY - 2005/11

Y1 - 2005/11

N2 - Although imatinib mesylate (IM) is highly effective at inducing complete cytogenetic remission in patients with chronic myelogenous leukemia (CML), it is known to suppress T-cell proliferation in vitro. As cytokines are required for T-cell proliferation, we investigated the effects of IM on cytokine synthesis by T cells of CML patients by assessing cytokine synthesis by activated CD4+ and CD8+ T cells in vitro. The activation of T cells in the whole blood of IM-treated patients (CML-IM) with Staphylococcus enterotoxin B resulted in significantly lower percentages of CD4+ T cells that synthesized interleukin 2 (P = 0.017), interferon-gamma (P = 0.010), and tumor necrosis factor-alpha (P = 0.009) than did the activated T cells of control subjects. The addition of exogenous IM to the cultures of peripheral blood mononuclear cells of CML-IM patients reduced Th1 cytokine synthesis by the CD4+ T cells. Furthermore, IM therapy at clinical doses suppressed the tyrosine phosphorylation of ZAP70. These findings suggest that inhibition of ZAP70 signaling pathway and suppression of Th1 cytokine synthesis by CD4+ T cells required the presence of IM at the time of T-cell activation through the T-cell receptor.

AB - Although imatinib mesylate (IM) is highly effective at inducing complete cytogenetic remission in patients with chronic myelogenous leukemia (CML), it is known to suppress T-cell proliferation in vitro. As cytokines are required for T-cell proliferation, we investigated the effects of IM on cytokine synthesis by T cells of CML patients by assessing cytokine synthesis by activated CD4+ and CD8+ T cells in vitro. The activation of T cells in the whole blood of IM-treated patients (CML-IM) with Staphylococcus enterotoxin B resulted in significantly lower percentages of CD4+ T cells that synthesized interleukin 2 (P = 0.017), interferon-gamma (P = 0.010), and tumor necrosis factor-alpha (P = 0.009) than did the activated T cells of control subjects. The addition of exogenous IM to the cultures of peripheral blood mononuclear cells of CML-IM patients reduced Th1 cytokine synthesis by the CD4+ T cells. Furthermore, IM therapy at clinical doses suppressed the tyrosine phosphorylation of ZAP70. These findings suggest that inhibition of ZAP70 signaling pathway and suppression of Th1 cytokine synthesis by CD4+ T cells required the presence of IM at the time of T-cell activation through the T-cell receptor.

KW - Chronic myelogenous leukemia

KW - Cytokines

KW - Imatinib mesylate

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=27644449731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644449731&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403933

DO - 10.1038/sj.leu.2403933

M3 - Article

C2 - 16151467

AN - SCOPUS:27644449731

VL - 19

SP - 1905

EP - 1911

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 11

ER -